Remarkably, phosphatases can influence the response to TKI treatment as reported for PTPN1 (PTP1B) (38), PTPN6 (SHP1) (39) and PTPRC (CD45) (40) for BCR-ABL TKIs treatment in chronic myeloid leukemia or for PTPN11 (SHP2) for acquired resistance to ALK-TKIs in ALK-rearranged non-small cell lung cancer (NSCLC) (41). This evidence concerns the gene BCR and non-small cell lung carcinoma.